NanoBiCAR has published its official project flyer, presenting the project’s vision, innovative approach and expected impact in the fight against resistant bacterial infections.
The flyer introduces NanoBiCAR’s ambition to develop a next-generation immunotherapeutic approach for infectious diseases, using tuberculosis as a proof of concept and addressing the growing global challenge of antimicrobial resistance.
NanoBiCAR explores the use of mRNA-loaded lipid nanoparticles to enable the in vivo production of immunotherapeutic agents designed to help the immune system recognise and eliminate infected cells and extracellular bacteria. This approach aims to contribute to new therapeutic strategies that go beyond conventional antibiotic-based treatments.
The flyer summarises the main elements of the project, including:
- The global challenge posed by bacterial infections and antimicrobial resistance;
- The NanoBiCAR vision for a new immunotherapeutic paradigm;
- The project’s innovative mRNA-based approach;
- The expected impact for tuberculosis and other difficult-to-treat infections;
- The role of the multidisciplinary NanoBiCAR consortium.
This communication material will support the project’s dissemination activities and help present NanoBiCAR to scientific, clinical, industrial, institutional and general audiences.